GeneDx is trading 8% down at $62.43 in after-hours trading following the release of its Q2 2026 financial results, which showed a wider-than-expected GAAP loss.
- While the company beat revenue estimates with $114.4 million and reported strong volume growth, it missed on GAAP EPS and only reaffirmed its full-year 2026 guidance.
- The mixed results prompted profit-taking from investors despite the company achieving a modest adjusted net income for the quarter.
- The negative price action was further influenced by thinner trading volumes typical of the after-hours session.